SCHEMBL25189635

SCHEMBL25189635

CC(C)c1ncc(C=O)cc1NC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 5/20 0.37
▸ METAP1 P53582 1/20 0.37
▸ CYP17A1 P05093 1/20 0.36
▸ ATR Q13535 1/20 0.36
▸ BRD9 Q9H8M2 1/20 0.35
▸ IDO1 P14902 2/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ BACE1 P56817 1/20 0.35
▸ PRKDC P78527 1/20 0.35
▸ PI4KB Q9UBF8 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ P2RX3 P56373 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25186768 0.84 TRPV1 (0.42) METAP1BRD9IDO1EGFRRXFP1
SCHEMBL20169942 0.83 CYP17A1 (0.38) AAK1METAP1CYP17A1ATRBRD9
SCHEMBL25186778 0.82 LCK (0.39) AAK1METAP1CYP17A1BRD9IDO1
SCHEMBL24069253 0.77 BRD4 (0.41) AAK1METAP1ATRBRD4
SCHEMBL30209740 0.77 BRD4 (0.41) AAK1METAP1ATRBRD4
SCHEMBL6478595 0.74 HPGD (0.44) CYP17A1ATRBRD9RXFP1
SCHEMBL17604700 0.73 KDM4E (0.44) CYP17A1ATRPOLB
SCHEMBL22842983 0.72 IDO1 (0.38) METAP1CYP17A1ATRBRD9IDO1
SCHEMBL2825756 0.71 NAMPT (0.46) CYP17A1ATRIDO1
SCHEMBL479056 0.71 NAMPT (0.43) CYP17A1ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA BOSTON INC. 2025-05-01 — — US disclosed
EP-4430028-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) 2024-09-18 — — EP disclosed
WO-2023086428-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2023-05-19 — — WO disclosed
WO-2023086428-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF AHR, ARNT, NR1H2 AAK1 1511/4885METAP1 1171/4885CYP17A1 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback